温阳利水方联合腹腔热灌注化疗治疗卵巢癌腹水临床观察及作用机制研究  

Clinical Observation and Study of Mechanism of Applying Wenyang Lishui Decoction Combined with Intraperitoneal Chemotherapy in the Treatment of ovarian Cancer Patients with Ascites Hyperthermic Perfusion

作　　者：张毅鹏[1] 张金秋 洪月光[1] ZHANG Yipeng;ZHANG Jinqiu;Hong Yueguang(Department of Oneology, Qinhuangdao Municipal Traditonal Chinese Medicine Hospital （ Qinhuangdao Hebei 066000, China;Department of Gynecology, Qinhuangdao Municipal Maternal and Child Health Care Hospital （ Qinhuangdao Hebei 066099, China)

机构地区：[1]秦皇岛市中医医院肿瘤科,河北秦皇岛066000 [2]秦皇岛市妇幼保健院妇科,河北秦皇岛066001

出　　处：《四川中医》2018年第6期157-160,共4页Journal of Sichuan of Traditional Chinese Medicine

摘　　要：目的:观察温阳利水方联合腹腔热灌注化疗治疗卵巢癌腹水患者的临床治疗效果及其对作用机制的研究。方法:选取卵巢癌腹水患者85例,随机分为对照组及观察组,对照组41例,观察组44例。2组患者均采用紫杉醇+顺铂行腹腔热灌注化疗,而观察组在对照组基础上加用温阳利水方治疗,2组均继续治疗4疗程。观察比较治疗前后2组患者血清中T细胞的亚群(CD_3^+、CD_4^+、CD_8^+、CD_4^+/CD_8^+)变化;比较治疗后2组KPS评分,2组治疗前、治疗2个疗程及4个疗程后的腹腔积液量;腹水情况临床疗效及安全性评价。结果:治疗后观察组患者的CD_3^+、CD_4^+及CD_4^+/CD_8^+均明显高于治疗前,并且也显著高于对照组患者(P<0.05)。治疗后观察组KPS评分均明显优于对照组;观察组治疗后2疗程和4疗程腹腔积液量明显少于对照组(P<0.05);腹水情况临床评价观察组RR及DCR均优于对照组;毒副反应明显少于对照组(P>0.05)。结论:温阳利水方联合腹腔热灌注化疗治疗卵巢癌腹水患者具有良好的临床疗效,值得在临床上推广。Objective： To observe the clinical therapeutic effect of Wenyang Lishui Decoction combined with intraperitoneal hyperthermic perfusion chemotherapy in the treatment of ovarian cancer ascites patients and study on the mechanism. Methods： 85cases of ascites in ovarian cancer patients were randomly divided into controlled group and observation group, 41cases in the controlled group, 44cases in the observation group. 2groups of patients were treated with paclitaxel plus cisplatin intraperitoneal perfusion chemotherapy, and the observation group treated with Wenyang Lishui Decoction on the basisi of the controlled group, the 2groups were treated for 4courses. T cells were observed before and after treatment in the 2groups of patients in the subgroups （CD3^＋, CD4^＋, CD8^＋, CD4^＋/CD8^＋） ; After treatment between the 2groups in KPS score, 2groups before treatment, treatment of ascites volume 2treatment and 4after treatment of ascites, clinical efficacy and safety evaluation. Results： After treatment, the CD3^＋, CD4^＋ and CD4^＋/CD8^＋ in the observation group were significantly higher than before treatment, and also significantly higher than that in the controlled group （ P〈0.05 ）. After treatment, the KPS score of the observation group were significantly better than the controlled group. The observation group after treatment of 2course and the 4course of peritoneal effusion volume was signifi- cantly less than the controlled group （P〈0.05）. Clinical evaluation of ascites were observed in group RR and DCR were better than the controlled group, toxicity was significantly less than the controlled group （P〉0. 05 ）. Conclusion： It has a good clinical effect on Wenyang Lishui Decoction combined with intraperitoneal hyperthermic perfusion chemotherapy in the treatment of ovarian cancer ascites patients, worthy of clinical popularization.

关 键 词：温阳利水 CD4^+/CD8^+ 卵巢癌 KPS 

分 类 号：R737.71[医药卫生—肿瘤]